Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-14

FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for ledipasvir and sofosbuvir from Asegua Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

SUPPL AP for LEDIPASVIR AND SOFOSBUVIR (LEDIPASVIR AND SOFOSBUVIR)